Shalini virani <br/><br/>
Efficacy,safety, and cost-effectiveness of biosimilars of bevacizumab in naive patients with diabetic macular edema 

 - PP248-252 
<br/><br/><label>Subjects--Facted Index Terms: </label><br/>Anti-vascular endothelial growth factor<br/>bevacizumab <br/>biosimilars <br/>cost-effectiveness<br/>diabetic macular edema